ASBP
NASDAQ · Pharmaceuticals
Aspire Biopharma Holdings In
$7.80
+0.74 (+10.48%)
Financial Highlights (FY 2026)
Revenue
159.7K
Net Income
-630,621,419
Gross Margin
-1.9%
Profit Margin
-394,852.4%
Rev Growth
—
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | -1.9% | 63.6% | 63.6% | 63.6% |
| Operating Margin | -317,990.3% | 15.9% | 17.9% | 17.2% |
| Profit Margin | -394,852.4% | 12.1% | 14.9% | 13.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 159.7K | 2.20M | 2.09M | 2.38M |
| Gross Profit | -3,097 | 1.40M | 1.33M | 1.51M |
| Operating Income | -507,770,122 | 350.5K | 374.4K | 410.4K |
| Net Income | -630,621,419 | 266.8K | 312.0K | 325.1K |
| Gross Margin | -1.9% | 63.6% | 63.6% | 63.6% |
| Operating Margin | -317,990.3% | 15.9% | 17.9% | 17.2% |
| Profit Margin | -394,852.4% | 12.1% | 14.9% | 13.7% |
| Rev Growth | — | +5.7% | +22.2% | +15.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.0K | 703.8K | 744.6K | 770.5K |
| Total Equity | 5.00M | 1.66M | 1.82M | 1.58M |
| D/E Ratio | 0.00 | 0.42 | 0.41 | 0.49 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -507,864,404 | 501.0K | 520.7K | 532.7K |
| Free Cash Flow | — | 197.3K | 259.9K | 336.6K |